Bliss GVS Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Bliss GVS Pharma Ltd reported a 8.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 18.8%.
• Its expenses for the quarter were up by 24.5% QoQ and 19.7% YoY.
• The net profit decreased 35.6% QoQ and increased 11.3% YoY.
• The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 2.54 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bliss GVS Pharma Ltd is a pharmaceutical company engaged primarily in the manufacturing and marketing of a range of pharmaceutical products. The company's offerings include a variety of formulations in therapeutic areas such as antibiotics, anti-malarial, and anti-inflammatory drugs. Bliss GVS Pharma Ltd operates within the healthcare and pharmaceuticals industry, which is characterized by stringent regulations and a focus on research and development for new drug formulations. As of the data available up to October 2023, there are no specific recent major developments or acquisitions noted for the company.

Revenue

For Q2FY26, Bliss GVS Pharma Ltd reported a total income of ₹264.58 crores. This marks an increase of 8.9% quarter-over-quarter (QoQ) from ₹242.92 crores in Q1FY26 and an 18.8% increase year-over-year (YoY) from ₹222.72 crores in Q2FY25. The company's revenue growth both on a quarterly and annual basis reflects a positive trend in its income generation capabilities, driven by its pharmaceutical operations. The observed increase in total income suggests a robust performance in the company's sales or service offerings over the specified periods.

Profitability

Bliss GVS Pharma Ltd recorded a profit before tax of ₹40.63 crores in Q2FY26, a decrease of 35.6% QoQ from ₹63.11 crores in Q1FY26. However, when compared YoY, this figure represents a 13.8% increase from ₹35.71 crores in Q2FY25. The tax expense for Q2FY26 was ₹12.04 crores, also showing a decrease of 35.8% QoQ from ₹18.75 crores in Q1FY26 and a 20.3% increase YoY from ₹10.01 crores in Q2FY25. The profit after tax for Q2FY26 amounted to ₹28.59 crores, down 35.6% QoQ from ₹44.36 crores in Q1FY26, but up 11.3% YoY from ₹25.69 crores in Q2FY25. Earnings per share were ₹2.54, which is a decrease of 37.1% QoQ from ₹4.04 and an increase of 10.9% YoY from ₹2.29.

Operating Metrics

The total expenses for Bliss GVS Pharma Ltd in Q2FY26 were ₹223.94 crores, showing an increase of 24.5% QoQ from ₹179.81 crores in Q1FY26 and a 19.7% increase YoY from ₹187.01 crores in Q2FY25. This rise in expenses may be attributed to various operational or production costs associated with the company's pharmaceutical activities. The significant increase in expenses compared to the increase in income is a notable trend in this period. The financial data for Q2FY26 reflects typical operational challenges faced by companies in the pharmaceutical sector, which often include fluctuating cost structures and investment in product development and marketing.